In-stent restenosis: Mid-term results of debulking using excimer laser and drug-eluting balloons: Sustained benefit?

Journal of Invasive Cardiology

Volumn 26, Issue 7, 2014, Pages 333-337

  Van Den Berg, Jos C ^a   Pedrotti, Milko ^a   Canevascini, Reto ^a   Chimchila Chevili, Sonia ^a   Giovannacci, Luca ^a   Rosso, Raffaele ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

drug eluting balloons; in stent restenosis; laser atherectomy

Indexed keywords

AGED; AMPUTATION; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL ARTICLE; CRITICAL LIMB ISCHEMIA; DRUG ELUTING STENT; EXCIMER LASER; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; ADVERSE EFFECTS; ARTERY; COHORT ANALYSIS; CONSTRICTION, PATHOLOGIC; CYTOREDUCTIVE SURGERY; INGUINAL CANAL; LASER ANGIOPLASTY; PROCEDURES; PROSPECTIVE STUDY; RECURRENT DISEASE; RETROSPECTIVE STUDY; THERAPEUTIC USE; TIME; TREATMENT OUTCOME; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; ANGIOPLASTY, BALLOON, LASER-ASSISTED; ARTERIES; COHORT STUDIES; CONSTRICTION, PATHOLOGIC; CYTOREDUCTION SURGICAL PROCEDURES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INGUINAL CANAL; LASERS, EXCIMER; MALE; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903946579     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Diehm NA, Hoppe H, Do DD. Drug-eluting balloons. Tech Vasc Interv Radiol. 2010;13(1): 59-63.
2. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3): 267-276.
3. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115(21): 2745-2749.
4. Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20(9): 1141-1150.
5. Schillinger M, Mlekusch W, Haumer M, Sabeti S, Ahmadi R, Minar E. Angioplasty and elective stenting of de novo versus recurrent femoropopliteal lesions: 1-year follow-up. J Endovasc Ther. 2003;10(2): 288-297.
6. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology. 2008;248(1): 297-302.
7. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59(1): 16-23.
8. Farb A, Kolodgie FD, Hwang JY, et al. Extracellular matrix changes in stented human coronary arteries. Circulation. 2004;110(8): 940-947.
9. Inoue S, Koyama H, Miyata T, Shigematsu H. Pathogenetic heterogeneity of in-stent lesion formation in human peripheral arterial disease. J Vasc Surg. 2002;35(4): 672-678.
10. Osherov AB, Gotha L, Cheema AN, Qiang B, Strauss BH. Proteins mediating collagen biosynthesis and accumulation in arterial repair: novel targets for anti-restenosis therapy. Cardiovasc Res. 2011;91(1): 16-26.
11. Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58(3): 682-686.
12. Armstrong EJ, Singh S, Singh GD, et al. Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention. Catheter Cardiovasc Interv. 2013;82(7):1168-1174. Epub 2013 Jun 3.
13. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13): 1358-1365.
14. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7): 689-699.
15. Adiguzel E, Ahmad PJ, Franco C, Bendeck MP. Collagens in the progression and complications of atherosclerosis. Vasc Med. 2009;14(1): 73-89.
16. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008;97(10): 773-781.
17. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23): 2986-2994.
18. Stabile E, Virga V, Salemme L, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60(18): 1739-1742.
19. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6): 831-840.
20. Ho GH, van Buren PA, Moll FL, van der Bom JG, Eikelboom BC. The importance of revision of early restenosis after endovascular remote endarterectomy in SFA occlusive disease. Eur J Vasc Endovasc Surg. 2000;19(1): 35-42.
21. Derksen WJ, Gisbertz SS, Hellings WE, et al. Predictive risk factors for restenosis after remote superficial femoral artery endarterectomy. Eur J Vasc Endovasc Surg. 2010;39(5): 597-603.
22. Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78(4): 611-617.
23. Ihnat DM, Duong ST, Taylor ZC, et al. Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score. J Vasc Surg. 2008;47(5):967-974. Epub 2008 Apr 18.